BIO-RAD LABORATORIES -CL B (BIO.B) Stock Fundamental Analysis
USA - NYSE:BIO.B - US0905721082 - Common Stock
284.875 USD
+27.13 (+10.52%)
BIO.B gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. BIO.B has an excellent financial health rating, but there are some minor concerns on its profitability. BIO.B is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BIO.B had positive earnings in the past year.
BIO.B had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BIO.B reported negative net income in multiple years.
Each year in the past 5 years BIO.B had a positive operating cash flow.
1.2 Ratios
BIO.B has a Return On Assets of -22.71%. This is in the lower half of the industry: BIO.B underperforms 65.45% of its industry peers.
BIO.B has a worse Return On Equity (-32.40%) than 60.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 2.70%, BIO.B is in the better half of the industry, outperforming 61.82% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for BIO.B is significantly below the industry average of 15.96%.
The 3 year average ROIC (2.69%) for BIO.B is below the current ROIC(2.70%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.71% | ||
| ROE | -32.4% | ||
| ROIC | 2.7% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
BIO.B has a Operating Margin of 12.14%. This is in the better half of the industry: BIO.B outperforms 69.09% of its industry peers.
BIO.B's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 53.68%, BIO.B is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
BIO.B's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.14% | ||
| PM (TTM) | N/A | ||
| GM | 53.68% |
OM growth 3Y-15.52%
OM growth 5Y1.14%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO.B is destroying value.
Compared to 1 year ago, BIO.B has less shares outstanding
The number of shares outstanding for BIO.B has been reduced compared to 5 years ago.
Compared to 1 year ago, BIO.B has a worse debt to assets ratio.
2.2 Solvency
BIO.B has an Altman-Z score of 3.21. This indicates that BIO.B is financially healthy and has little risk of bankruptcy at the moment.
BIO.B has a Altman-Z score of 3.21. This is in the better half of the industry: BIO.B outperforms 65.45% of its industry peers.
The Debt to FCF ratio of BIO.B is 3.62, which is a good value as it means it would take BIO.B, 3.62 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of BIO.B (3.62) is better than 70.91% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that BIO.B is not too dependend on debt financing.
The Debt to Equity ratio of BIO.B (0.18) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.62 | ||
| Altman-Z | 3.21 |
ROIC/WACC0.33
WACC8.13%
2.3 Liquidity
A Current Ratio of 5.99 indicates that BIO.B has no problem at all paying its short term obligations.
BIO.B's Current ratio of 5.99 is amongst the best of the industry. BIO.B outperforms 81.82% of its industry peers.
A Quick Ratio of 4.43 indicates that BIO.B has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.43, BIO.B is in the better half of the industry, outperforming 70.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.99 | ||
| Quick Ratio | 4.43 |
3. Growth
3.1 Past
BIO.B shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.11%.
Measured over the past 5 years, BIO.B shows a small growth in Earnings Per Share. The EPS has been growing by 7.84% on average per year.
BIO.B shows a decrease in Revenue. In the last year, the revenue decreased by -3.92%.
Measured over the past years, BIO.B shows a small growth in Revenue. The Revenue has been growing by 2.11% on average per year.
EPS 1Y (TTM)-7.11%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-16.08%
Revenue 1Y (TTM)-3.92%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%2.06%
3.2 Future
BIO.B is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.33% yearly.
The Revenue is expected to grow by 1.35% on average over the next years.
EPS Next Y-17.35%
EPS Next 2Y-4.67%
EPS Next 3Y1.5%
EPS Next 5Y-4.33%
Revenue Next Year-2.19%
Revenue Next 2Y0.57%
Revenue Next 3Y1.77%
Revenue Next 5Y1.35%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 28.32 indicates a quite expensive valuation of BIO.B.
Based on the Price/Earnings ratio, BIO.B is valued a bit cheaper than 72.73% of the companies in the same industry.
When comparing the Price/Earnings ratio of BIO.B to the average of the S&P500 Index (27.38), we can say BIO.B is valued inline with the index average.
The Price/Forward Earnings ratio is 30.40, which means the current valuation is very expensive for BIO.B.
Based on the Price/Forward Earnings ratio, BIO.B is valued a bit cheaper than the industry average as 69.09% of the companies are valued more expensively.
BIO.B is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.86, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.32 | ||
| Fwd PE | 30.4 |
4.2 Price Multiples
81.82% of the companies in the same industry are more expensive than BIO.B, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.35 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.61
EPS Next 2Y-4.67%
EPS Next 3Y1.5%
5. Dividend
5.1 Amount
No dividends for BIO.B!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:BIO.B (9/19/2025, 8:04:00 PM)
284.875
+27.13 (+10.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.78%
Inst Owner Change-26.18%
Ins Owners3.67%
Ins Owner ChangeN/A
Market Cap7.75B
Analysts76.36
Price Target369.39 (29.67%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.53%
Min EPS beat(2)0.1%
Max EPS beat(2)38.97%
EPS beat(4)4
Avg EPS beat(4)40.99%
Min EPS beat(4)0.1%
Max EPS beat(4)72.05%
EPS beat(8)7
Avg EPS beat(8)21.55%
EPS beat(12)8
Avg EPS beat(12)14.41%
EPS beat(16)12
Avg EPS beat(16)19.4%
Revenue beat(2)1
Avg Revenue beat(2)-0.8%
Min Revenue beat(2)-2.71%
Max Revenue beat(2)1.11%
Revenue beat(4)2
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)2.41%
Revenue beat(8)2
Avg Revenue beat(8)-2.22%
Revenue beat(12)3
Avg Revenue beat(12)-1.99%
Revenue beat(16)6
Avg Revenue beat(16)0.12%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-3.36%
EPS NQ rev (3m)-30.61%
EPS NY rev (1m)-2.06%
EPS NY rev (3m)-12.45%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)-3.11%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-1.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.32 | ||
| Fwd PE | 30.4 | ||
| P/S | 3.05 | ||
| P/FCF | 23.35 | ||
| P/OCF | 15.05 | ||
| P/B | 1.16 | ||
| P/tB | 1.3 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.06
EY3.53%
EPS(NY)9.37
Fwd EY3.29%
FCF(TTM)12.2
FCFY4.28%
OCF(TTM)18.93
OCFY6.64%
SpS93.39
BVpS245.46
TBVpS219.33
PEG (NY)N/A
PEG (5Y)3.61
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.71% | ||
| ROE | -32.4% | ||
| ROCE | 3.42% | ||
| ROIC | 2.7% | ||
| ROICexc | 3.31% | ||
| ROICexgc | 3.67% | ||
| OM | 12.14% | ||
| PM (TTM) | N/A | ||
| GM | 53.68% | ||
| FCFM | 13.07% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.19%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexcg growth 3Y8.28%
ROICexcg growth 5Y0.09%
ROICexc growth 3Y5.96%
ROICexc growth 5Y-0.55%
OM growth 3Y-15.52%
OM growth 5Y1.14%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.62 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 7.2% | ||
| Interest Coverage | -6.57 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.99 | ||
| Quick Ratio | 4.43 | ||
| Altman-Z | 3.21 |
F-Score5
WACC8.13%
ROIC/WACC0.33
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.76%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.11%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-16.08%
EPS Next Y-17.35%
EPS Next 2Y-4.67%
EPS Next 3Y1.5%
EPS Next 5Y-4.33%
Revenue 1Y (TTM)-3.92%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%2.06%
Revenue Next Year-2.19%
Revenue Next 2Y0.57%
Revenue Next 3Y1.77%
Revenue Next 5Y1.35%
EBIT growth 1Y-9.77%
EBIT growth 3Y-19.1%
EBIT growth 5Y3.28%
EBIT Next Year22.43%
EBIT Next 3Y13.71%
EBIT Next 5Y6.41%
FCF growth 1Y162.24%
FCF growth 3Y-20.82%
FCF growth 5Y-5.84%
OCF growth 1Y112.81%
OCF growth 3Y-12.08%
OCF growth 5Y-0.13%